RLS
MCID: RST001
MIFTS: 54

Restless Legs Syndrome (RLS)

Categories: Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Restless Legs Syndrome

MalaCards integrated aliases for Restless Legs Syndrome:

Name: Restless Legs Syndrome 12 74 52 25 53 36 54 43 15 62 17 71
Restless Leg Syndrome 52 25
Willis-Ekbom Disease 12 25
Wed 12 25
Wittmaack-Ekbom Syndrome 12
Willis Ekbom Disease 52
Ekbom's Syndrome 25
Ekbom Syndrome 25
Restless Legs 42
Rls 25

Classifications:



External Ids:

Disease Ontology 12 DOID:0050425
KEGG 36 H01597
ICD9CM 34 333.94
MeSH 43 D012148
NCIt 49 C84501
SNOMED-CT 67 32914008
ICD10 32 G25.81
UMLS 71 C0035258

Summaries for Restless Legs Syndrome

Genetics Home Reference : 25 Restless legs syndrome is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, often described as crawling, pulling, or itching, deep within both legs. The feelings usually occur while the affected person is sitting or lying down and are worse at night. Movement, such as kicking, stretching, rubbing, or pacing, make the discomfort go away, at least temporarily. The unpleasant feelings and the resulting need to move the legs often make it difficult for an affected person to fall asleep or stay asleep. The signs and symptoms of restless legs syndrome range from mild to severe; people with mild cases may experience symptoms a few times a month, while those with more severe cases may have symptoms every night. In severe cases, the uncomfortable feelings can affect the arms or other parts of the body in addition to the legs. Many people with restless legs syndrome also experience uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. When these movements occur during sleep, they are called periodic limb movements of sleep (PLMS); when they occur while a person is awake, they are called periodic limb movements of wakefulness (PLMW). It is unclear whether PLMS and PLMW are features of restless legs syndrome itself or represent similar, but separate, conditions. Restless legs syndrome and PLMS can affect the quality and amount of sleep. As a result of these conditions, affected individuals may have difficulty concentrating during the day, and some develop mood swings, depression, or other health problems. Researchers have described early-onset and late-onset forms of restless legs syndrome. The early-onset form begins before age 45, and sometimes as early as childhood. The signs and symptoms of this form usually worsen slowly with time. The late-onset form begins after age 45, and its signs and symptoms tend to worsen more rapidly.

MalaCards based summary : Restless Legs Syndrome, also known as restless leg syndrome, is related to restless legs syndrome 6 and restless legs syndrome 7, and has symptoms including seizures, tremor and back pain. An important gene associated with Restless Legs Syndrome is RLS1 (Restless Legs Syndrome, Susceptibility To), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Apomorphine and Trimetazidine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and kidney.

Disease Ontology : 12 A central nervous system disease characterized by throbbing, pulling creeping or other unpleasant sensations in the legs and the irresistible urge to move them.

NIH Rare Diseases : 52 Restless legs syndrome (RLS) is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, which occur mostly while the affected person is sitting or lying down and are worse at night. Movement (i.e. kicking, stretching, rubbing, or pacing) makes the discomfort go away, at least temporarily. Many people with restless legs syndrome also have uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. Researchers have described early-onset and late-onset forms of restless legs syndrome. The early-onset form begins before age 45 and progresses slowly. The late-onset form begins after age 45, and its signs and symptoms tend to worsen more rapidly. RLS likely results from a combination of genetic and environmental factors , many of which are unknown. The syndrome may also be classified in several types (RLS1, RLS2, RLS3, RLS4, RLS5, RLS6, RLS7) according to the location in specific chromosomes of some of the genes that are associated with an increased risk (susceptibility ) to have the syndrome. Treatment is based on the signs and symptoms present in each person.

MedlinePlus : 42 Restless legs syndrome (RLS) causes a powerful urge to move your legs. Your legs become uncomfortable when you are lying down or sitting. Some people describe it as a creeping, crawling, tingling, or burning sensation. Moving makes your legs feel better, but not for long. RLS can make it hard to fall asleep and stay asleep. In most cases, there is no known cause for RLS. In other cases, RLS is caused by a disease or condition, such as anemia or pregnancy. Some medicines can also cause temporary RLS. Caffeine, tobacco, and alcohol may make symptoms worse. Lifestyle changes, such as regular sleep habits, relaxation techniques, and moderate exercise during the day can help. If those don't work, medicines may reduce the symptoms of RLS. Most people with RLS also have a condition called periodic limb movement disorder (PLMD). PLMD is a condition in which a person's legs twitch or jerk uncontrollably, usually during sleep. PLMD and RLS can also affect the arms. NIH: National Heart, Lung, and Blood Institute

NINDS : 53 Restless legs syndrome (RLS) is characterized by unpleasant sensations in the legs and an irresistible urge to move them. Individuals affected with the disorder often describe the sensations as throbbing, pulling, or creeping. The sensations range in severity from uncomfortable to irritating to painful. Symptoms commonly occur in late afternoon or evening and are most severe at night, when the person is resting. Moving the legs or walking typically relieves the discomfort but the symptoms often recur. RLS is both a sleep and a neurological sensory disorder.

KEGG : 36 The restless legs syndrome (RLS), also known as Willis Ekbom disease is a neurologic disorder characterized by unpleasant sensations in the legs accompanied by an urge to move them (akathisia). These symptoms occur predominantly at rest and worsen at night, resulting in nocturnal insomnia and chronic sleep deprivation. The prevalence of RLS increases with age and appears to be higher among women than among men. RLS has a high familial aggregation. To date, several loci and genetic risk factors have been identified, but no causative gene mutation has been found. Standard medications for RLS are dopamine agonists and CACN alpha-2 delta blocker. A high prevalence of iron deficiency has been found among patients with RLS. It has been reported that treatment with oral iron supplements resulted in improvements in the severity of the symptoms in patients with a low serum ferritin level.

PubMed Health : 62 About restless legs syndrome: Restless legs syndrome (RLS) is a disorder that causes a strong urge to move your legs. This urge to move often occurs with strange and unpleasant feelings in your legs. Moving your legs relieves the urge and the unpleasant feelings. People who have RLS describe the unpleasant feelings as creeping, crawling, pulling, itching, tingling, burning, aching, or electric shocks. Sometimes, these feelings also occur in the arms. The urge to move and unpleasant feelings happen when you're resting and inactive. Thus, they tend to be worse in the evening and at night.

Wikipedia : 74 Restless legs syndrome (RLS) is generally a long-term disorder that causes a strong urge to move one's... more...

Related Diseases for Restless Legs Syndrome

Diseases in the Restless Legs Syndrome family:

Restless Legs Syndrome 1 Restless Legs Syndrome 2
Restless Legs Syndrome 3 Restless Legs Syndrome 4
Restless Legs Syndrome 6 Restless Legs Syndrome 5
Restless Legs Syndrome 7 Restless Legs Syndrome 8

Diseases related to Restless Legs Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 460)
# Related Disease Score Top Affiliating Genes
1 restless legs syndrome 6 35.4 RLS6 BTBD9
2 restless legs syndrome 7 35.4 RLS7 MEIS1
3 periodic limb movement disorder 33.6 HCRT DRD2 BTBD9
4 migraine with or without aura 1 32.1 HCRT DRD4 DRD3 DRD2 DRD1
5 movement disease 32.0 DRD4 DRD3 DRD2 DRD1
6 mental depression 31.7 DRD4 DRD3 DRD2 DRD1
7 anxiety 31.6 HCRT DRD4 DRD3 DRD2
8 bruxism 31.6 HCRT DRD3 DRD2 DRD1
9 pathological gambling 31.5 DRD4 DRD3 DRD2 DRD1
10 migraine without aura 31.5 DRD4 DRD3 DRD2 DRD1
11 choreatic disease 31.5 DRD4 DRD3 DRD2 DRD1
12 mood disorder 31.5 DRD4 DRD3 DRD2 DRD1
13 impulse control disorder 31.4 DRD4 DRD3 DRD2 DRD1
14 major depressive disorder 31.4 HCRT DRD4 DRD3 DRD2 DRD1
15 panic disorder 31.3 DRD4 DRD3 DRD2 DRD1
16 eating disorder 31.3 HCRT DRD3 DRD2
17 gilles de la tourette syndrome 31.2 DRD4 DRD3 DRD2 DRD1 BTBD9
18 tic disorder 31.1 DRD4 DRD3 DRD2 DRD1 BTBD9
19 trichotillomania 31.1 DRD4 DRD3 DRD2
20 sexual disorder 31.1 DRD4 DRD3 DRD2
21 substance abuse 31.1 DRD4 DRD3 DRD2 DRD1
22 obsessive-compulsive disorder 31.1 PTPRD DRD4 DRD3 DRD2 DRD1
23 kleptomania 31.0 DRD4 DRD3 DRD2
24 delusional disorder 30.9 DRD4 DRD3 DRD2 DRD1
25 opiate dependence 30.9 DRD4 DRD3 DRD2 DRD1
26 gastroparesis 30.9 DRD4 DRD3 DRD2 DRD1
27 personality disorder 30.8 DRD4 DRD3 DRD2
28 drug dependence 30.7 DRD3 DRD2 DRD1
29 schizoaffective disorder 30.6 DRD4 DRD3 DRD2
30 alcohol use disorder 30.6 DRD3 DRD2 DRD1
31 autism spectrum disorder 30.2 HCRT DRD4 DRD3 DRD2 DRD1
32 restless legs syndrome 2 12.9
33 restless legs syndrome 1 12.9
34 restless legs syndrome 3 12.9
35 restless legs syndrome 4 12.9
36 restless legs syndrome 5 12.9
37 restless legs syndrome 8 12.8
38 sleep disorder 11.8
39 machado-joseph disease 11.7
40 fibromyalgia 11.6
41 roussy-levy hereditary areflexic dystasia 11.4
42 persistent genital arousal disorder 11.2
43 iron metabolism disease 11.1
44 end stage renal disease 10.9
45 neuropathy 10.8
46 sleep apnea 10.8
47 polyneuropathy 10.8
48 attention deficit-hyperactivity disorder 10.8
49 peripheral nervous system disease 10.7
50 parkinson disease, late-onset 10.7

Graphical network of the top 20 diseases related to Restless Legs Syndrome:



Diseases related to Restless Legs Syndrome

Symptoms & Phenotypes for Restless Legs Syndrome

UMLS symptoms related to Restless Legs Syndrome:


seizures, tremor, back pain, headache, syncope, excessive daytime somnolence, pain, chronic pain, sciatica, snoring, sleep disturbances, vertigo/dizziness, sleeplessness

Drugs & Therapeutics for Restless Legs Syndrome

PubMed Health treatment related to Restless Legs Syndrome: 62

Restless legs syndrome (RLS) has no cure. If a condition or medicine triggers RLS, it may go away or get better if the trigger is relieved or stopped. RLS can be treated. The goals of treatment are to: Prevent or relieve symptoms Increase the amount of sleep you're getting and improve the quality of your sleep Treat or correct any underlying condition that may trigger or worsen RLS Mild cases of RLS often are treated with lifestyle changes and sometimes with periodic use of medicines. More severe RLS usually is treated with daily medicines.

Drugs for Restless Legs Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 165)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
2
Trimetazidine Approved, Investigational Phase 4 5011-34-7
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
6
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
9
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
10
Levetiracetam Approved Phase 4 102767-28-2 441341
11
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
12
Topiramate Approved Phase 4 97240-79-4 5284627
13
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
14
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
15
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
18
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
19
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
20
Amitriptyline Approved Phase 4 50-48-6 2160
21
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
22
Propranolol Approved, Investigational Phase 4 525-66-6 4946
23
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
24
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
25
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
26
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
27
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
28
Donepezil Approved Phase 4 120014-06-4 3152
29
Memantine Approved, Investigational Phase 4 19982-08-2 4054
30
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
31
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
32
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
34 Tocotrienol Investigational Phase 4 6829-55-6
35
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
36 Emetics Phase 4
37 Vasodilator Agents Phase 4
38 Antidepressive Agents Phase 4
39 Hypoglycemic Agents Phase 4
40 Sodium Potassium Chloride Symporter Inhibitors Phase 4
41 Cyclooxygenase 2 Inhibitors Phase 4
42 Anti-Inflammatory Agents Phase 4
43 Cyclooxygenase Inhibitors Phase 4
44 diuretics Phase 4
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4
46 Antirheumatic Agents Phase 4
47 Serotonin Uptake Inhibitors Phase 4
48 Cardiotonic Agents Phase 4
49 Sympathomimetics Phase 4
50 Dopamine agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 Effects of Gabapentin Enacarbil on Intensity of Cortical Arousal, Heart Rate, Blood Pressure and Anterior Tibialis EMG Responses Associated With PLMs During Sleep in Patients With RLS Using a Novel Computer Assisted Scoring System Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
2 Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease Unknown status NCT02940912 Phase 4 Apomorphine;Placebo
3 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
4 A Method to Switch From Oral Dopamine Agonists to Rotigotine in Patients With Restless Legs Syndrome Completed NCT01976871 Phase 4 Rotigotine
5 Exploratory Study of the Efficacy, Practicability and Safety of Intravenous Iron Supplementation Therapy in Moderate to Severe Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Completed NCT01245777 Phase 4 ferric carboxymaltose
6 Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS Completed NCT02025608 Phase 4 Pramipexole;Placebo
7 A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep Completed NCT00373542 Phase 4 ropinirole CR-RLS
8 A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Severe Restless Legs Syndrome. Completed NCT00329602 Phase 4 Placebo;Ropinirole
9 Gabapentin Enacarbil Post-marketing Clinical Study A Randomized, Double-blind, Placebo-controlled, Parallel-group Study in Subjects With Restless Legs Syndrome. Completed NCT03053427 Phase 4 Placebo;Gabapentin enacarbil
10 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome Completed NCT00349531 Phase 4 Pramipexole
11 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances Completed NCT00356096 Phase 4 pramipexole
12 Post-marketing Clinical Study of Gabapentin Enacarbil ―Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment― Completed NCT01981941 Phase 4 Gabapentin enacarbil
13 Multicenter, Double-Blind, Placebo-Controlled, Two-Arm, Randomized, Parallel, Treatment Intervention, Sleep Lab Phase 4 Study to Assess the Effect of Rotigotine on Nocturnal Blood Pressure in Patients With Idiopathic Restless Legs Syndrome Completed NCT01455012 Phase 4 Rotigotine;Placebo
14 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period Completed NCT00472199 Phase 4 Pramipexole;Placebo
15 A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome Completed NCT00375284 Phase 4 Pramipexole
16 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effacy and Safety of Topiramate in Subjects With Restless Legs Syndrome (RLS) Completed NCT00200941 Phase 4 Topiramate
17 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome : a Pilot Randomized, Placebo-controlled Study Completed NCT01823770 Phase 4 Rotigotine;Placebo patchs
18 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS) Completed NCT01668667 Phase 4 GSK1838262 600 mg;GSK1838262 450 mg;GSK1838262 300 mg;GSK1838262 Placebo match
19 A Prospective, Randomized Study Evaluating the Efficacy and Safety of Early Diuresis Following Colorectal Surgery Completed NCT02351934 Phase 4 Furosemide;Celecoxib;Gabapentin
20 An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose Completed NCT00344994 Phase 4 pramipexole
21 Treatment of Sexual Dysfunction Secondary to Antidepressant Pharmacotherapy: A Double-blind Comparison of Requip (Ropinirole) vs. Placebo in Patients Taking SSRI Antidepressants Completed NCT00334048 Phase 4 Ropinirole (Requip)
22 Comparison of Analgesic Effects of Gabapentin and Paracetamol in Patients With Hand Injury Completed NCT04068506 Phase 4 Gabapentin 600 mg Tab
23 Gabapentin as an Adjunct for Pain Management During Dilation and Evacuation: A Double-blind Randomized Controlled Trial Completed NCT03635905 Phase 4 Gabapentin;Placebo
24 A Randomized Controlled Trial of Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients Recruiting NCT03817554 Phase 4 Pramipexole
25 Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease Recruiting NCT03082755 Phase 4 Gabapentin Enacarbil;Placebo Oral Tablet
26 Pilot Study to Gain First Indications for the Impact of a Three-month's Oral Intake of an Iron Supplement With High Bioavailability on the Hemoglobin Concentration in Iron Deficient Blood Donors Recruiting NCT04250298 Phase 4
27 A Multicenter, Double-Blind, Placebo Controlled, Parallel Group, Efficacy and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary RLS Active, not recruiting NCT02560766 Phase 4 HORIZANT 300 mg;HORIZANT 600 mg;Placebo
28 A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome Active, not recruiting NCT02633683 Phase 4 HORIZANT 600 mg
29 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
30 Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis Enrolling by invitation NCT03176966 Phase 4 Vitamin E;Ropinirole
31 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Suspended NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
32 Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome Terminated NCT02117076 Phase 4 Gabapentin immediate release;Gabapentin enacarbil extended release
33 The Effect of Gabapentin on Postoperative Pain: a Randomized, Double Blind, Placebo Controlled Trial Terminated NCT01546857 Phase 4 Placebo;Gapabentin
34 Butrans for Treatment of Restless Legs Syndrome Withdrawn NCT02138357 Phase 4 buprenorphine transdermal delivery system (BTDS);Placebo for BTDS patch
35 Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome Withdrawn NCT00584246 Phase 4 Pregabalin (Lyrica);Placebo
36 A Randomised Clinical Trial Comparing Standard Cannula Delivered Foam Sclerotherapy, Catheter Directed Foam Sclerotherapy and ClariVein® Mechanochemical Ablation in the Management of Superficial Venous Insufficiency. Withdrawn NCT02010437 Phase 4 Sodium Tetradecyl Sulphate (STS)
37 Vitamin D in the Treatment of Primary Restless Legs Syndrome: 12 Weeks, Triple-blinded, Randomized, Placebo-controlled Trial Unknown status NCT02256215 Phase 2, Phase 3 Vitamin D
38 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00135993 Phase 3 Rotigotine
39 Long-term Study - Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients Completed NCT02658188 Phase 3 ASP8825
40 A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome Completed NCT00197080 Phase 3 Ropinirole Extended Release (XR)
41 A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS) Completed NCT00314860 Phase 3 ropinirole Extended Release (XR)
42 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome. Completed NCT00298623 Phase 3 XP13512 (GSK1838262)
43 A 12-week, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Intermittent Dosing of Ropinirole in Patients With Restless Legs Syndrome (RLS) Completed NCT00225862 Phase 3 ropinirole
44 A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks Completed NCT00654498 Phase 3 Pramipexole;Placebo
45 A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS) Completed NCT00363857 Phase 3 Ropinirole
46 A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography Study Of Pregabalin And Pramipexole In Adults With Restless Legs Syndrome Completed NCT00991276 Phase 3 pregabalin;placebo;pramipexole
47 A Multi-center, Randomized, Double-blind, Placebo-controlled, Four-arm Parallel-group Trial to Investigate the Efficacy and Safety of Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome Completed NCT00136045 Phase 3 Rotigotine
48 A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS) Completed NCT00355641 Phase 3 Ropinirole Extended Release (XR)
49 A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks Completed NCT00133198 Phase 3 Pramipexole
50 A Multi-center, Double-blind, Randomized, Placebo-controlled, Two-arm, Parallel-group, Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00275236 Phase 3 Rotigotine

Search NIH Clinical Center for Restless Legs Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carbamazepine
Clonazepam

Cochrane evidence based reviews: restless legs syndrome

Genetic Tests for Restless Legs Syndrome

Anatomical Context for Restless Legs Syndrome

MalaCards organs/tissues related to Restless Legs Syndrome:

40
Brain, Heart, Kidney, Testes, Spinal Cord, Lung, Liver

Publications for Restless Legs Syndrome

Articles related to Restless Legs Syndrome:

(show top 50) (show all 3903)
# Title Authors PMID Year
1
Acupuncture for restless legs syndrome: A systematic review and meta-analysis protocol. 42 61
32011519 2020
2
Acupuncture and Moxibustion for restless legs syndrome: A systematic review and meta-analysis protocol. 61 42
31977877 2020
3
Intractable Restless Legs Syndrome - Look for Other Causes. 42 61
32200395 2020
4
Circadian variation of hypocretin-1 (orexin A) in restless legs syndrome. 61 54
19013101 2009
5
Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. 54 61
18207455 2009
6
Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography. 61 54
16941469 2006
7
Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. 54 61
16816393 2006
8
Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. 54 61
16268375 2005
9
CSF iron, ferritin and transferrin levels in restless legs syndrome. 61 54
15743333 2005
10
Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. 54 61
15136682 2004
11
Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study. 61 54
12242538 2002
12
Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. 61 54
12196669 2002
13
Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. 54 61
10762522 2000
14
The convenient use of fluorescamine for spectrofluorimetric quantitation of pramipexole in pure form and pharmaceutical formulation; application to content uniformity testing. 61
32413715 2020
15
'Is RLS a harbinger and consequence of MS?: Striking results of the 'RELOMS-T' study'. 61
32473575 2020
16
Effects of repetitive transcranial magnetic stimulation in subjects with sleep disorders. 61
32173186 2020
17
Contribution of transcranial magnetic stimulation in restless legs syndrome: pathophysiological insights and therapeutical approaches. 61
32088150 2020
18
The present and the future of Transcranial Magnetic Stimulation in Restless Legs Syndrome. 61
32151506 2020
19
Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome. 61
32094092 2020
20
Developing a behavioral model of Restless Legs Syndrome utilizing mice with natural variances in ventral midbrain iron. 61
32044226 2020
21
Restless legs syndrome among multiple sclerosis patients in Lebanon. 61
32113183 2020
22
Restless legs syndrome and health-related quality of life in adults with multiple sclerosis. 61
31157499 2020
23
Comparison of prevalence rates of restless legs syndrome, self-assessed risks of obstructive sleep apnea, and daytime sleepiness among patients with multiple sclerosis (MS), clinically isolated syndrome (CIS) and Neuromyelitis Optica Spectrum Disorder (NMOSD). 61
32276200 2020
24
Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. 61
32546134 2020
25
Associations between sleep problems and ADHD symptoms among adolescents: findings from the Shandong Adolescent Behavior and Health Cohort (SABHC). 61
31790135 2020
26
Iron deficiency and sleep - A scoping review. 61
32224451 2020
27
Structural neuroimaging findings in migraine patients with restless legs syndrome. 61
32488307 2020
28
Hypothyroidism in restless legs syndrome. 61
32483857 2020
29
Restless Legs Syndrome and Severe Preeclampsia: A Case-Control Study. 61
32576450 2020
30
SKOR1 has a transcriptional regulatory role on genes involved in pathways related to restless legs syndrome. 61
32572201 2020
31
The urge to move: From restless legs syndrome to impulse control disorders in Parkinson's disease. 61
32542856 2020
32
Pharmacologic and Nonpharmacologic Treatment of Restless Legs Syndrome. 61
32386701 2020
33
Serum Glycomics Profiling of Patients with Primary Restless Legs Syndrome (RLS) using LC-MS/MS. 61
32483971 2020
34
Gender differences in clinical, laboratory and polysomnographic features of restless legs syndrome. 61
31162763 2020
35
Symptom-related changes in current perception threshold of restless legs syndrome. 61
31237744 2020
36
Peculiar lifespan changes of periodic leg movements during sleep in restless legs syndrome. 61
31313413 2020
37
Acute post-stroke restless legs syndrome: the body of caudate nucleus considerations. 61
32229419 2020
38
Restless legs syndrome, sleep over the lifespan, sleep in the severely ill, shift-work and sleep loss. 61
32449288 2020
39
Better Objective Sleep Was Associated with Better Subjective Sleep and Physical Activity; Results from an Exploratory Study under Naturalistic Conditions among Persons with Multiple Sclerosis. 61
32443481 2020
40
Practice patterns of board-certified sleep medicine providers: a national analysis among older adult Medicare beneficiaries. 61
32024587 2020
41
Thermo-therapy and cryotherapy to decrease the symptoms of restless leg syndrome during the pregnancy: A randomized clinical trial. 61
32444058 2020
42
Perampanel in chronic insomnia. 61
32078957 2020
43
The prevalence of restless legs syndrome in patients undergoing coronary angiography and its relationship with the severity of coronary artery stenosis. 61
32430676 2020
44
Restless legs syndrome, sleep quality, and perceived cognitive impairment in adults with multiple sclerosis. 61
32498034 2020
45
Treatment of restless legs syndrome with a pump; efficacy and complications. 61
31883387 2020
46
BTBD9 and dopaminergic dysfunction in the pathogenesis of restless legs syndrome. 61
32468214 2020
47
Alterations in Salience Network Functional Connectivity in Individuals with Restless Legs Syndrome. 61
32377013 2020
48
CSF and serum ferritin levels in narcolepsy type 1 comorbid with restless legs syndrome. 61
32432412 2020
49
Mu opioid receptor knockout mouse: Phenotypes with implications on restless legs syndrome. 61
32424971 2020
50
Selective serotonin reuptake inhibitors and the risk of restless legs syndrome: a symmetry analysis. 61
32062781 2020

Variations for Restless Legs Syndrome

Expression for Restless Legs Syndrome

Search GEO for disease gene expression data for Restless Legs Syndrome.

Pathways for Restless Legs Syndrome

GO Terms for Restless Legs Syndrome

Cellular components related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.73 TFRC HCRT DRD4 DRD3 DRD2 DRD1
2 dopaminergic synapse GO:0098691 9.16 DRD3 DRD2
3 GABA-ergic synapse GO:0098982 9.13 DRD3 DRD2 DRD1
4 glutamatergic synapse GO:0098978 9.02 PTPRD DRD4 DRD3 DRD2 DRD1

Biological processes related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.85 MEIS1 DRD3 DRD2 DRD1
2 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.81 DRD3 DRD2 DRD1
3 visual learning GO:0008542 9.8 DRD3 DRD2 DRD1
4 response to cocaine GO:0042220 9.79 DRD3 DRD2 DRD1
5 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.78 DRD3 DRD2 DRD1
6 feeding behavior GO:0007631 9.77 HCRT DRD2 DRD1
7 negative regulation of protein secretion GO:0050709 9.74 DRD4 DRD3 DRD2
8 arachidonic acid secretion GO:0050482 9.73 DRD4 DRD3 DRD2
9 temperature homeostasis GO:0001659 9.71 HCRT DRD2 DRD1
10 response to amphetamine GO:0001975 9.71 DRD4 DRD3 DRD2 DRD1
11 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.7 DRD3 DRD2 DRD1
12 negative regulation of voltage-gated calcium channel activity GO:1901386 9.69 DRD4 DRD3 DRD2
13 negative regulation of adenylate cyclase activity GO:0007194 9.68 DRD3 DRD2
14 negative regulation of cytosolic calcium ion concentration GO:0051481 9.68 DRD3 DRD2
15 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.68 DRD3 DRD2
16 positive regulation of renal sodium excretion GO:0035815 9.67 DRD3 DRD2
17 grooming behavior GO:0007625 9.67 DRD2 DRD1
18 G protein-coupled receptor internalization GO:0002031 9.67 DRD3 DRD2
19 prepulse inhibition GO:0060134 9.67 DRD3 DRD2 DRD1
20 striatum development GO:0021756 9.66 DRD2 DRD1
21 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.66 DRD4 DRD3
22 regulation of potassium ion transport GO:0043266 9.65 DRD3 DRD2
23 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.65 DRD3 DRD1
24 regulation of dopamine metabolic process GO:0042053 9.65 DRD4 DRD1
25 behavioral response to ethanol GO:0048149 9.65 DRD4 DRD3 DRD2
26 peristalsis GO:0030432 9.64 DRD2 DRD1
27 cerebral cortex GABAergic interneuron migration GO:0021853 9.63 DRD2 DRD1
28 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.63 DRD3 DRD2 DRD1
29 regulation of neurotransmitter uptake GO:0051580 9.62 DRD3 DRD2
30 dopamine receptor signaling pathway GO:0007212 9.62 DRD4 DRD3 DRD2 DRD1
31 negative regulation of dopamine receptor signaling pathway GO:0060160 9.61 DRD3 DRD2
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.61 DRD4 DRD3 DRD2
33 regulation of locomotion involved in locomotory behavior GO:0090325 9.59 DRD3 DRD2
34 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.58 DRD4 DRD2
35 acid secretion GO:0046717 9.58 DRD3 DRD2
36 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.54 DRD3 DRD2 DRD1
37 behavioral response to cocaine GO:0048148 9.46 DRD4 DRD3 DRD2 DRD1
38 response to histamine GO:0034776 9.43 DRD4 DRD3 DRD2
39 synaptic transmission, dopaminergic GO:0001963 9.26 DRD4 DRD3 DRD2 DRD1
40 dopamine metabolic process GO:0042417 8.92 DRD4 DRD3 DRD2 DRD1

Molecular functions related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.5 DRD4 DRD3 DRD2
2 adrenergic receptor activity GO:0004935 9.43 DRD3 DRD2 DRD1
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD4 DRD3 DRD2
4 dopamine binding GO:0035240 9.26 DRD4 DRD3 DRD2 DRD1
5 dopamine neurotransmitter receptor activity GO:0004952 8.92 DRD4 DRD3 DRD2 DRD1

Sources for Restless Legs Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....